Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The voltage-gated calcium channel beta subunit (variant) is a specialized regulatory protein found in parasitic platyhelminths, such as Schistosoma and Taenia species (Jeziorski & Greenberg, 2006). It functions as an auxiliary subunit to the pore-forming alpha1 subunit of voltage-gated calcium channels, modulating channel trafficking to the plasma membrane and adjusting gating kinetics (Greenberg, 2014). This specific variant is characterized by structural differences from mammalian beta subunits, which renders the parasite's calcium channels uniquely sensitive to certain pharmacological agents (Park & Marchant, 2012). It plays a pivotal role in the neuromuscular coordination and tegumental integrity of the parasite, making it a vital target for anthelmintic drugs.\n\nThe primary drug interacting with this target is praziquantel, which acts as an allosteric modulator to induce a conformational change in the channel complex (Park & Marchant, 2012). This interaction leads to a massive and rapid influx of calcium ions, causing immediate spastic paralysis of the parasite's musculature and significant vacuolization of its protective tegument (Jeziorski & Greenberg, 2006). The resulting damage exposes parasite antigens to the host's immune system, leading to the clearance of the infection. Because this variant is distinct from human calcium channel subunits, it provides a high degree of therapeutic selectivity. However, the lack of efficacy against juvenile stages and the potential for emerging drug resistance remain significant therapeutic challenges (Greenberg, 2014).
Allosteric modulation of the voltage-gated calcium channel complex via the variant beta subunit, leading to increased calcium permeability and parasite paralysis (Park & Marchant, 2012; Greenberg, 2014).
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Voltage-gated calcium channel beta subunit (variant) (Cav-beta).